The cost of systemic sclerosis

Area of Science:

• Rheumatology
• Health Economics
• Public Health

Background:

• Systemic sclerosis (SSc) is a chronic autoimmune disease with significant health implications.
• Understanding the economic burden of SSc is crucial for resource allocation and patient support.
• Previous studies have not comprehensively assessed the direct and indirect costs associated with SSc in Canada.

Purpose of the Study:

• To determine the annual direct and indirect costs for patients with systemic sclerosis (SSc).
• To identify key determinants influencing the economic burden of SSc.
• To provide updated cost data in 2007 Canadian dollars.

Main Methods:

• Data from 457 adult SSc patients across 15 Canadian centers were analyzed.
• Direct medical costs were calculated using health service utilization and unit prices.
• Indirect costs included productivity losses from paid and unpaid labor.

Main Results:

• The average annual direct cost per SSc patient was $5,038.
• Indirect costs, including lost productivity, averaged $13,415 per patient annually.
• Total average annual costs reached $18,453 per patient, influenced by disease severity and health status.

Conclusions:

• Systemic sclerosis presents a considerable economic burden on patients.
• Disease severity and overall health status are significant factors driving the costs associated with SSc.
• These findings highlight the need for effective management strategies to mitigate the financial impact of SSc.